Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Current Assets (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Current Assets data on record, last reported at $353.8 million in Q4 2025.

  • For Q4 2025, Current Assets rose 32.82% year-over-year to $353.8 million; the TTM value through Dec 2025 reached $353.8 million, up 32.82%, while the annual FY2025 figure was $353.8 million, 32.82% up from the prior year.
  • Current Assets reached $353.8 million in Q4 2025 per TNGX's latest filing, up from $163.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $516.3 million in Q3 2021 and bottomed at $734293.0 in Q2 2021.
  • Average Current Assets over 5 years is $312.3 million, with a median of $344.8 million recorded in 2023.
  • Peak YoY movement for Current Assets: surged 59288.42% in 2022, then plummeted 45.55% in 2025.
  • A 5-year view of Current Assets shows it stood at $492.3 million in 2021, then fell by 23.78% to $375.3 million in 2022, then fell by 7.66% to $346.5 million in 2023, then dropped by 23.14% to $266.3 million in 2024, then surged by 32.82% to $353.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $353.8 million in Q4 2025, $163.8 million in Q3 2025, and $190.1 million in Q2 2025.